#Global Fragment Based Drug Discovery Market Size

[colinwilson11]

Smart Drug Design Through Fragment-Based Approaches Will Drive Growth In The Global Fragment Based Drug Discovery Market

The fragment based drug discovery approach involves screening libraries of very small molecules called fragments that bind to targets of therapeutic interest with low molecular weight and high binding efficiency. These fragments act as starting points for developing potential drug candidates. Compared to high-throughput screening, fragment-based methods require smaller libraries that can be easily synthesized and screened. Fragment hits have low affinity but high efficiency that improves the probability of growing them into potent and selectiveligands through structure based drug design.

The Global Fragment Based Drug Discovery Market is estimated to be valued at US$ 0.795 Bn in 2024 and is expected to exhibit a CAGR of 15% over the forecast period 2024-2031.

Key players operating in the fragment based drug discovery market include Astex Pharmaceuticals, Beactica AB, Charles River Laboratories International, Inc., Evotec AG, and Alveus Pharmaceuticals Pvt. Ltd.

Key Takeaways

Key players operating in the fragment based drug discovery market are focusing on expanding their fragment libraries and enhancing screening capabilities to identify novel hits. For instance, in 2022, Astex Pharmaceuticals significantly expanded its fragment library collection to over 450,000 fragments to enable robust hit identification.

The growing incidence of chronic diseases coupled with rising drug discovery and development activities is fueling the demand for fragment-based techniques. Fragment based screening allows developing biologically relevant leads with superior physiochemical and pharmacological properties compared to high-throughput screening.

Technological advancements in biophysical methods such as NMR, crystallography, mass spectrometry and computational modeling tools have widened the application scope of fragment based approaches in hit identification and optimization stages of drug R&D. In 2023, Evotec AG introduced the PanOmics platform to integrate omics data for enhancing fragment hits using systems chemical biology approaches.

Market Trends

De-risking drug candidates: Fragment based screening enables identifying low risk hits bound to attractive regions of target proteins with high efficiency. By optimizing these fragments, drug candidates with lower biological and chemical liability can be developed.

Integrating biophysical methods: Combining multiple biophysical techniques such as X-ray crystallography, NMR spectroscopy, SPR, and SBM provides comprehensive structural and binding information for fragment evolutions and optimization.

Leveraging artificial intelligence: Machine learning and deep learning based computational tools are being increasingly used to process, analyze and interpret large experimental datasets generated through fragment screening campaigns to facilitate hit discovery and design.

Market Opportunities

Growing collaboration between pharmaceutical companies and academic research institutes is expected to boost knowledge sharing and resource optimization for fragment libraries creation and screening. Moreover, increasing R&D investments and funding support from governments and private organizations will facilitate clinical research on fragment-derived drug candidates.

Impact Of COVID-19 On Global Fragment Based Drug Discovery Market:

The COVID-19 pandemic has significantly impacted the Global Fragment Based Drug Discovery Market. During the initial lockdown phase, drug discovery activities were disrupted as research labs and facilities were shut down to curb the virus spread. This led to delays in lab experiments, screening programs and drug development timelines. Researchers faced difficulties in accessing facilities for fragment screening, biophysical analyses and hit validation studies. Supply chain disruptions also created shortages of laboratory consumables and reagents required for fragment based screening assays.

However, as restrictions eased in late 2020, companies resumed operations with new safety protocols. Many shifted their focus towards developing treatments and vaccines for COVID-19. Fragments screening emerged as a promising approach for rapidly identifying potent antiviral hits against the SARS-CoV-2 virus. Several academic and pharmaceutical institutions employed their expertise and infrastructure in fragment based drug design to speed up the search for COVID-19 therapies. Government and private funding also increased for coronavirus drug development projects utilizing fragment screening techniques.

Going forward, companies are expected to leverage learnings from the pandemic. More efficient hybrid models blending onsite and remote working may be adopted. Fragment screening capabilities will be expanded to enable rapid response against future health emergencies. Enhanced collaborations between industry and academia can help expedite drug discovery programs. Overall, with resurgence plans and improved resilience, the long-term impact of COVID-19 on the fragmented based drug discovery market is expected to be positive.

Geographical Regions Of Concentrated Market Value:

The global fragmented based drug discovery market in terms of value is highly concentrated in North American and European countries. The United States holds the largest market share currently due to strong presence of leading pharmaceutical and biotechnology companies. Many top players have their core research and development centres located in the US and are involved in internal and collaborative fragment screening programs. Europe is also a major revenue generator owing to substantial investments in drug discovery research by both private sector and government research councils in countries like Germany, United Kingdom and France.

Fastest Growing Region:

The Asia Pacific region is anticipated to experience the highest growth in the global fragmented based drug discovery market over the forecast period. Factors such as increasing government focus on enhancing domestic innovation, rising biopharmaceutical industry investments, and growing skilled workforce availability are fueling market expansion in Asia Pacific. Countries like China, India and South Korea are emerging hubs for low-cost high quality contract research and manufacturing. This is attracting several multinational companies to establish fragment screening centers and collaborations in Asia to tap growth opportunities. Additionally, improving Intellectual Property (IP) frameworks and favorable business policies will further support market penetration of fragmented based drug discovery technologies across Asia Pacific.

Get more insights on this topic:https://www.trendingwebwire.com/global-fragment-based-drug-discovery-market-is-estimated-to-witness-high-growth-owing-to-technological-advancement-in-fragment-based-screening-techniques/

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)

What Are The Key Data Covered In This Global Fragment Based Drug Discovery Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Global Fragment Based Drug Discovery Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Global Fragment Based Drug Discovery Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Global Fragment Based Drug Discovery Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Global Fragment Based Drug Discovery Market vendors

FAQ’s

Q.1 What are the main factors influencing the Global Fragment Based Drug Discovery Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Global Fragment Based Drug Discovery Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Global Fragment Based Drug Discovery Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[janetushar1]

AI in Drug Discovery Market to Hit $7.1 Billion by 2032

The global AI in Drug Discovery Market was valued at USD 1.3 Billion in 2024 and it is estimated to garner USD 7.1 Billion by 2032 with a registered CAGR of 23.72% during the forecast period 2024 to 2032.

The report throws light on the competitive scenario of the global AI in Drug Discovery Market to know the competition at global levels. Market experts also provided the outline of each leading player of the global AI in Drug Discovery Market for the market, considering the key aspects such as the areas of operation, production, and product portfolio. In addition, the companies in the report are studied based on vital factors such as company size, market share, market growth, revenue, production volume, and profit.

The global AI in Drug Discovery Market is fragmented with various key players. Some of the key players identified across the value chain of the global AI in Drug Discovery Market include IBM Corporation (US), Microsoft (US), and Google (US), NVIDIA Corporation (US), Atomwise, Inc. (US), Deep Genomics (Canada), Cloud Pharmaceuticals (US), Insilico Medicine (US), BenevolentAI (UK), Exscientia (UK), Cyclica (Canada), BIOAGE (US), Numerate (US), NuMedii (US), Envisagenics (US), twoXAR (US), OWKIN, Inc. (US), XtalPi (US), Verge Genomics (US), and BERG LLC (US). etc. Considering the increasing demand from global markets various new entries are expected in the AI in Drug Discovery Market at regional as well as global levels.

Download AI in Drug Discovery Market Sample Report PDF: https://www.vantagemarketresearch.com/artificial-intelligence-in-drug-discovery-market-1239/request-sample

Top Competitors:

IBM Corporation (US), Microsoft (US), and Google (US), NVIDIA Corporation (US), Atomwise, Inc. (US), Deep Genomics (Canada), Cloud Pharmaceuticals (US), Insilico Medicine (US), BenevolentAI (UK), Exscientia (UK), Cyclica (Canada), BIOAGE (US), Numerate (US), NuMedii (US), Envisagenics (US), twoXAR (US), OWKIN, Inc. (US), XtalPi (US), Verge Genomics (US), and BERG LLC (US).

Understanding the Industry's Growth, has released an Updated report on the AI in Drug Discovery Market. The report is mixed with crucial market insights that will support the clients to make the right business decisions. This research will help new players in the global AI in Drug Discovery Market to sort out and study market needs, market size, and competition. The report provides information on the supply and market situation, the competitive situation and the challenges to the market growth, the market opportunities, and the threats faced by the major players.

Regional Analysis

-North America [United States, Canada, Mexico]

-South America [Brazil, Argentina, Columbia, Chile, Peru]

-Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

-Middle East & Africa [GCC, North Africa, South Africa]

-Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]

You Can Buy This Report From Here: https://www.vantagemarketresearch.com/buy-now/artificial-intelligence-in-drug-discovery-market-1239/0

Full Analysis Of The AI in Drug Discovery Market:

Key findings and recommendations point to vital progressive industry trends in the global AI in Drug Discovery Market, empowering players to improve effective long-term policies.

The report makes a full analysis of the factors driving the development of the market.

Analyzing the market opportunities for stakeholders by categorizing the high-growth divisions of the market.

Questions answered in the report

-Who are the top five players in the global AI in Drug Discovery Market?

-How will the global AI in Drug Discovery Market change in the next five years?

-Which product and application will take the lion's share of the global AI in Drug Discovery Market?

-What are the drivers and restraints of the global AI in Drug Discovery Market?

-Which regional market will show the highest growth?

-What will be the CAGR and size of the global AI in Drug Discovery Market during the forecast period?

Read Full Research Report with [TOC] @ https://www.vantagemarketresearch.com/industry-report/artificial-intelligence-ai-in-drug-discovery-market-2220

Reasons to Purchase this AI in Drug Discovery Market Report:

-Analysis of the market outlook on current trends and SWOT analysis.

-The geographic and country level is designed to integrate the supply and demand organizations that drive industry growth.

-AI in Drug Discovery Industry dynamics along with market growth opportunities in the coming years.

-AI in Drug Discovery Market value (million USD) and volume (million units) data for each segment and sub-segment.

1 year consulting for analysts along with development data support in Excel. Competitive landscape including market share of major players along with various projects and strategies adopted by players in the last five years.

Market segmentation analysis including qualitative and quantitative analysis including the impact on financial and non-economic aspects.

Complete company profiles that include performance presentations, key financial overviews, current developments, SWOT analyzes and strategies used by major AI in Drug Discovery Market players.

Check Out More Reports

Global Skincare Market:  Report Forecast by 2032

Global Behavioral Mental Health Software Market: Report Forecast by 2032

Global Dual Interface Payment Card Market: Report Forecast by 2032

Global Cold Chain Market: Report Forecast by 2032

Global Food Can Market: Report Forecast by 2032

[prajwal-agale001]

NGS Market Insights: The Role of Sequencing in Precision Medicine

The global next-generation sequencing (NGS) market is on the verge of unprecedented growth, with an expected market size of $27.5 billion by 2030, according to the latest report from Meticulous Research®. With a compound annual growth rate (CAGR) of 15.8% from 2023 to 2030, the NGS industry is being propelled by a confluence of factors that promise to transform medical diagnostics, research, and pharmaceutical development.

NGS technology, which allows rapid sequencing of DNA and RNA, has revolutionized genomics research and medical diagnostics over the past decade. The decreasing cost of genome sequencing, coupled with technological advancements, is expanding the reach of NGS across multiple industries and applications. However, as this technology matures, the market faces challenges, including high system costs and ethical concerns, even as new opportunities in bioinformatics and genomic data management continue to emerge.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5040?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=23-10-24

Key Growth Drivers of the NGS Market

Rising Cancer Prevalence and the Role of NGS in Cancer Research The increasing prevalence of cancer is a significant factor driving the growth of the NGS market. NGS has emerged as a powerful tool in cancer research, enabling the identification of genetic mutations, better understanding of tumor biology, and development of precision medicine. By allowing the sequencing of entire genomes or specific genes linked to cancer, NGS helps researchers and clinicians design targeted therapies, improving patient outcomes.

Declining Costs of Genome Sequencing As the cost of genome sequencing continues to decrease, NGS is becoming more accessible to a wider range of researchers, clinicians, and healthcare providers. What once cost millions of dollars now costs a fraction of that amount, making it possible for institutions and even smaller research facilities to incorporate NGS into their diagnostic and research workflows. The reduced financial barriers are expected to increase adoption, particularly in oncology, rare genetic diseases, and reproductive health.

Technological Advancements in Sequencing Procedures Innovations in sequencing technology have played a pivotal role in enhancing the accuracy, speed, and cost-effectiveness of NGS. Advances such as sequencing-by-synthesis and nanopore sequencing are boosting the adoption of NGS by offering improved accuracy, lower error rates, and the ability to sequence longer DNA fragments. These advancements allow for more comprehensive genomic analysis and have applications in fields such as agriculture, infectious diseases, and personalized medicine.

Surge in Genome Mapping Programs and Pharmaceutical R&D Investments Governments and research institutions across the world are investing heavily in genome mapping initiatives, further driving the demand for NGS technologies. Additionally, the rising expenditure in pharmaceutical research and development is spurring the need for high-throughput sequencing to identify potential drug targets and biomarkers. NGS enables pharmaceutical companies to conduct comprehensive genomic studies that support drug discovery and development, particularly in the fields of oncology, infectious diseases, and immunology.

Favorable Regulatory and Reimbursement Landscape Regulatory agencies and insurance companies are becoming more supportive of NGS-based diagnostic tests, which is encouraging market growth. In the U.S., the Food and Drug Administration (FDA) has approved several NGS-based tests for clinical use, while favorable reimbursement policies for NGS diagnostics are making it easier for patients to access these advanced tests. This regulatory support is crucial in accelerating the adoption of NGS technologies, particularly in clinical settings.

Market Challenges Hindering Growth

Despite the immense potential of the NGS market, certain challenges must be addressed to ensure sustainable growth.

High Costs of NGS Systems and Consumables While the cost of sequencing has dramatically decreased, the upfront costs of NGS systems and consumables remain high. The ongoing need for specialized consumables such as reagents, sample preparation kits, and sequencing chips can strain the budgets of research institutions and clinical labs. This financial barrier is particularly acute for small- and medium-sized enterprises (SMEs) and academic institutions, which may struggle to afford the high cost of NGS infrastructure.

Alternative Technologies The availability of alternative genomic technologies such as microarrays and polymerase chain reaction (PCR) poses a challenge to the growth of the NGS market. These alternatives, which are often less expensive and more established, continue to be widely used for certain types of genetic testing. While NGS offers superior depth and accuracy, its cost and complexity can make it less appealing for some routine diagnostics.

Ethical and Legal Concerns The widespread use of NGS, particularly in diagnostic testing, raises significant ethical and legal issues. Concerns over privacy, data ownership, and the potential for discrimination based on genetic information must be carefully navigated by companies in the NGS space. These ethical dilemmas, along with regulatory and standardization challenges, are obstacles that need to be addressed to ensure the responsible adoption of NGS technologies.

Have specific research needs? Request a customized research report- https://www.meticulousresearch.com/request-sample-report/cp_id=5040?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=23-10-24

Emerging Opportunities in the NGS Market

Despite these challenges, the future of the NGS market is bright, with several emerging opportunities poised to drive continued growth.

Expansion of Bioinformatics and Genomic Data Management Solutions The vast amounts of data generated by NGS require sophisticated bioinformatics tools for analysis and interpretation. As the demand for NGS continues to rise, so too will the need for advanced genomic data management solutions that can store, process, and analyze this data efficiently. The integration of AI and machine learning into bioinformatics platforms is expected to further enhance the capabilities of NGS in clinical and research applications.

Government Initiatives and Large-Scale Genomic Sequencing Projects Many governments around the world are launching large-scale genomic sequencing projects aimed at improving healthcare outcomes, particularly in precision medicine. These initiatives, such as the U.K.'s 100,000 Genomes Project and the U.S.'s All of Us Research Program, are expected to drive demand for NGS technologies. The growing global focus on personalized medicine and genetic research provides ample opportunities for NGS market expansion.

Increasing Automation and Development of Portable Sequencing Technologies Automation is becoming a key trend in the NGS market, with manufacturers developing automated platforms that streamline the sequencing process and reduce the need for manual intervention. Additionally, the development of portable and handheld sequencing technologies is expected to make NGS more accessible in point-of-care settings and remote areas. These advancements are likely to expand the reach of NGS beyond traditional research and clinical settings.

Growing Partnerships and Collaborations Collaborations among NGS instrument manufacturers, pharmaceutical companies, and academic institutions are becoming increasingly common as companies seek to expand their product offerings and improve their competitive positioning. These partnerships are expected to accelerate technological innovation and drive the development of new NGS applications across various industries, from healthcare and agriculture to forensics and environmental science.

Get A Glimpse Inside: Request Sample Pages - https://www.meticulousresearch.com/download-sample-report/cp_id=5040?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=23-10-24

Key Market Segments and Regional Overview

The global NGS market is segmented by offering, sequencing type, technology, application, end-user, and geography. Each segment plays a critical role in the overall growth dynamics of the industry.

By Offering: The consumables segment is expected to dominate the NGS market in 2023, driven by the recurring need for reagents and kits in research and diagnostic workflows.

By Sequencing Type: Targeted genome sequencing is projected to capture the largest share of the market due to its cost-effective nature and application in oncology and genetic research.

By Technology: Sequencing-by-synthesis is expected to lead the market in 2023, primarily due to its high accuracy and reliability in DNA sequencing.

By Application: The research and other applications segment, which includes drug discovery and agriculture, is set to hold the largest market share, fueled by the increasing use of NGS in genetic research.

By End-User: Pharmaceutical and biotechnology companies are expected to account for the largest share of the market, as NGS plays a crucial role in drug development and precision medicine.

Regional Overview: North America is forecasted to lead the global NGS market in 2023, driven by strong R&D investment, the presence of key market players, and favorable regulatory policies.

Conclusion

The global next-generation sequencing market is on a robust growth trajectory, fueled by technological innovations, declining costs, and increasing applications across multiple industries. As governments, research institutions, and private companies continue to invest in genomics, the demand for NGS is set to rise, paving the way for breakthroughs in precision medicine, cancer research, and beyond. However, challenges such as cost barriers, ethical concerns, and the need for skilled professionals must be addressed to fully realize the potential of this transformative technology.

Read Full Report - https://www.meticulousresearch.com/product/next-generation-sequencing-market-5040

Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

[market-insider]

Proteomics Market Forecast: Technological Advancements Shaping the Future

The global proteomics market size is expected to reach USD 58.16 billion by 2030, registering a CAGR of 13.10% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major factors driving theindustry growth are a rise in the demand for personalized medicine, an expansion of the pipeline of diagnostics utilizing proteomics mass spectrometry as well as biochip platforms, and discoveries based on genomics. Moreover, owing to the importance of proteomics in drug development, numerous pharmaceutical companies have established their own proteomic divisions, which are fueling the expansion of the global industry. For instance, in September 2021, Biognosys, announced the collaboration with Evotec, to promote the use of next-generation proteomics in clinical research and drug discovery.

The COVID-19 outbreak is expected to have a significant impact on the industry, as researchers across the world are concentrating on decoding 3D structures of SARS-CoV-2 proteins. To create effective medications and biological products against COVID-19, scientists are also attempting to examine the identification techniques, structures, characterization, and interactions of these proteins. The protein structure of virus proteins and their specific locations must be understood to find a novel, efficient target treatment medication for a virus. Therefore, it will increase the demand for drug development for COVID-19 and propel industry growth. The growing need for customized medications increased R&D spending, and technological developments related to proteomics components are also driving the market.

In addition, attractive market expansion potential for proteomics is anticipated to come from improvements in mass spectrometry-based proteomics and lucrative opportunities related to biomarker identification. Thereby, propelling the market growth.The introduction of new and improved proteomics techniques by major industry participants is projected to further accelerate the growth of the industry. For instance, to provide quick data acquisition for shotgun proteomics, Bruker Corp. introduced the timsTOF Pro system for Parallel Accumulation And Serial Fragmentation (PASEF) mass spectrometry in September 2017. This system uses proprietary Trapped Ion Mobility Spectrometry (TIMS) technology.Furthermore, proteomic research advancements have accelerated the detection of protein biomarkers, protein biochips & pharmacoproteomics, and proteomics-based molecular diagnostics, which have all made significant contributions to the development of personalized medicine.

For More Details or Sample Copy please visit link @: Proteomics Market Report

Proteomics Market Report Highlights

The reagent & consumables product segment held the largest share in 2023 due to rising research activities and the growing demand for protein separation from complicated mixtures for efficient analysis

The clinical diagnostics application segment held a larger share in 2023 due to the development of sophisticated & specialized tests for early disease detection and disease management

The spectroscopy technology segment held the maximum share in 2023 owing to the increasing usage in toxicological response profiling, basic molecular biology, biomarker identification, and pharmaceutical target screening

North America led the global industry in 2023 due to a rise in demand for personalized drugs, the existence of major players operating in the U.S. and a highly developed healthcare research framework, and substantial expenditure on R&D

Asia Pacific is expected to grow at the highest CAGR over the projected period due to factors, such as the rising prevalence of target diseases, increasing aging population, and rising proteomics adoption

Gain deeper insights on the market and receive your free copy with TOC now @: Proteomics Market Report

We have segmented the global proteomics market based on Product & services, application, technology, region.

[wellnessweb]

Key Players and Innovations Shaping the Apoptosis Assay Market Size

The Apoptosis Assay Market size was estimated USD 1.52 billion in 2023 and is expected to reach USD 3.21 billion by 2031 at a CAGR of 9.81% during the forecast period of 2024-2031. The Apoptosis Assay Market is rapidly evolving, driven by advancements in biomedical research and the increasing incidence of chronic diseases worldwide. This specialized market caters to the growing demand for precise and efficient methods to detect and quantify apoptotic cells, crucial for understanding disease mechanisms and developing targeted therapies. Innovations in assay technologies, such as flow cytometry, fluorescent microscopy, and PCR-based assays, are expanding the capabilities of researchers to analyze apoptosis with higher sensitivity and specificity. Additionally, the integration of artificial intelligence and machine learning algorithms is enhancing data interpretation and accelerating drug discovery processes. With a rising emphasis on personalized medicine, the apoptosis assay market is poised for significant growth, promising novel insights into cellular pathways and offering new avenues for therapeutic intervention in complex diseases like cancer and neurodegenerative disorders.

Get Sample Of The Report @ https://www.snsinsider.com/sample-request/3942

Market Scope & Overview

The Apoptosis Assay Market report's main goal is to provide readers with a better understanding of the industry, including market segmentation, potential, significant trends, and issues that developed and emerging nations must deal with. The research report's objective is to show how the current situation, the economic downturn, and COVID-19 have an impact on the entire industry.

The latest research report on Apoptosis Assay Market  market provides a thorough analysis of the factors affecting the scope of the global market. Our researchers, who keep an eye on the situation around the world, predict that the market will offer lucrative business opportunities for market participants.

Market Segmentation Analysis

By Assay Type

Caspase Assay

DNA Fragmentation Assay

Cell Permeability Assay

Mitochondrial Assay

By Product

Kits

Reagents

Instruments

By Technique

Flow Cytometry

Fluorescence Microscopy

Spectrophotometry

Other Techniques

By End User

Pharmaceutical & Biotechnology Companies

Hospital & Diagnostic Laboratories

Academic & Research Institutes

COVID-19 Impact Analysis

We routinely monitor Apoptosis Assay Market  changes and consumer behavior as the distinct coronavirus (COVID-19) problem spreads throughout the world. Then, while predicting the most recent market trends and forecasts, we take the epidemic's effects into account. Market participants who are developing strategies for pandemic-like events may find this information useful.

Regional Outlook

To predict the future course of the global Apoptosis Assay Market , advancements in each region are graphed using precise historical data. To evaluate the strengths, weaknesses, opportunities, and threats that these companies anticipate will exist throughout the projected period, a SWOT analysis is conducted.

Competitive Analysis

The most recent study carefully examines the businesses that compete in the Apoptosis Assay Market, including those that serve as suppliers of raw materials, equipment, end users, traders, and distributors. By carefully analyzing current supply and demand patterns, critical financial information of significant market participants, and the market's impact of recent economic changes, the research is intended to provide a 360-degree analysis of the global market.

Key Reasons to Buy Apoptosis Assay Market  Report

We can give you any extra details that aren't covered by the report as part of the research customization.

The competitive landscape section of the report contains comprehensive profiles of the key companies operating in the sector.

The research report covers impact analysis for COVID-19 pandemic period and post pandemic phase.

Conclusion

The Apoptosis Assay Market research report will help industry participants understand the strategies used by prosperous companies to prosper in the recent global market.

Read Full Report @ https://www.snsinsider.com/reports/apoptosis-assay-market-3942

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

BOTOX Market Growth

Botulinum Toxin Market Growth

Bovine Mastitis Market Growth

Brain Tumor Drugs Market Growth

Breast Cancer Therapeutics Market Growth

[lalsingh228-blog]

Active Pharmaceutical Ingredient Market Growing Popularity and Emerging Trends

The Latest research coverage on Active Pharmaceutical Ingredient Market provides a detailed overview and accurate market size. The study is designed considering current and historical trends, market development and business strategies taken up by leaders and new industry players entering the market. Furthermore, study includes an in-depth analysis of global and regional markets along with country level market size breakdown to identify potential gaps and opportunities to better investigate market status, development activity, value and growth patterns. Access Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/6098-global-active-pharmaceutical-ingredient-market

Major & Emerging Players in Active Pharmaceutical Ingredient Market:- Pfizer, Inc. (United States), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (United States), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (United States), GlaxoSmithKline plc (United Kingdom), Merck & Co., Inc. (United States). The Active Pharmaceutical Ingredient Market Study by AMA Research gives an essential tool and source to Industry stakeholders to figure out the market and other fundamental technicalities, covering growth, opportunities, competitive scenarios, and key trends in the Active Pharmaceutical Ingredient market. Active pharmaceutical ingredients (APIs) are good quality ingredients that are essential for the manufacture of effective & safe medicines. High prevalence & incidence rates of cancers, dental carries, cardiovascular diseases, back pain, & periodontal diseases drive the growth of the market. Demand for low-cost medicines & increase in the number of ANDA filings are fueling the growth of global active pharmaceutical ingredients market. Patent expiration of prominent drugs, favorable government initiatives, regional penetration & increasing aged population are some of the factors that are driving the market growth. Strict validation & safety guidelines stated by WHO & fragmented market are the factors that are hampering the growth of API market. Acquisitions and collaborations have been the key growth strategies adopted by players in the recent years. For example, In January 2018, Pfizer entered into a collaboration with Sangamo Therapeutics, Inc. (US) for the development of a potential gene therapy to treat amyotrophic lateral sclerosis (ALS) and in May 2018, Novartis acquired AveXis, a clinical-stage gene therapy company, to develop a gene-based treatment for spinal muscular atrophy.

The titled segments and sub-section of the market are illuminated below: by Type (Innovative, Generic), Application (Chemical, Deodorant, Others) Market Trends: Increasing Technological Advancements in API Manufacturing

Acceptance of Artificial Intelligence-Based Tools for Drug Discovery

Opportunities: Increasing Healthcare Expenditure

Growing Investments by Pharmaceutical Companies

Market Drivers: Growing Incidences of Chronic Diseases

Inclination towards Bio-pharmaceuticals products

Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/6098-global-active-pharmaceutical-ingredient-market Some Point of Table of Content: Chapter One: Report Overview Chapter Two: Global Market Growth Trends Chapter Three: Value Chain of Active Pharmaceutical Ingredient Market Chapter Four: Players Profiles Chapter Five: Global Active Pharmaceutical Ingredient Market Analysis by Regions Chapter Six: North America Active Pharmaceutical Ingredient Market Analysis by Countries Chapter Seven: Europe Active Pharmaceutical Ingredient Market Analysis by Countries Chapter Eight: Asia-Pacific Active Pharmaceutical Ingredient Market Analysis by Countries Chapter Nine: Middle East and Africa Active Pharmaceutical Ingredient Market Analysis by Countries Chapter Ten: South America Active Pharmaceutical Ingredient Market Analysis by Countries Chapter Eleven: Global Active Pharmaceutical Ingredient Market Segment by Types Chapter Twelve: Global Active Pharmaceutical Ingredient Market Segment by Applications What are the market factors that are explained in the Active Pharmaceutical Ingredient Market report?

– Key Strategic Developments: Strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors.

– Key Market Features: Including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin.– Analytical Tools: The analytical tools such as Porter’s five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market. Buy This Exclusive Research Here: https://www.advancemarketanalytics.com/buy-now?format=1&report=6098 Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market. Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. Contact US : Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 sales@advancemarketanalytics.com

[delvenservices]

Pathology AI Market Report Scope & Growth Opportunities

Pathology AI Market size is projected to reach USD 66.53 billion in 2030

Pathology AI (Artificial Intelligence) Market, by Component (Software, Services), Neural network (CNN, GAN, RNN), Application (Drug Discovery, Diagnosis, Prognosis, Workflow, Education), End User (Pharma, Biotech, Hospital Labs, Research) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).

Market Overview

The global Pathology AI (Artificial Intelligence) market size was estimated at USD 23.4 million in 2023 and is projected to reach USD 66.53 billion in 2030 at a CAGR of 16.1% during the forecast period 2023-2030.

The AI ​​Pathology Market can be defined as the integration of AI-based algorithms and machine learning techniques in the world of pathology. Pathology, a critical discipline in medicine, involves the study of tissues and cells to diagnose diseases, understand their progression, and guide treatment decisions. With the advent of artificial intelligence, this traditional practice is undergoing a profound transformation, supported by advanced computing capabilities that provide pathologists and healthcare providers with unprecedented insights.

Get the Free Sample Copy at: https://www.delvens.com/get-free-sample/pathology-ai-market-trends-forecast-till-2030

Increasing government initiatives to encourage healthcare providers and other healthcare organizations to adopt AI-based diagnostic technologies, as well as investments by non-profits and private companies for better data sharing, improved clinical outcomes and cost reduction are some of the expected key drivers. to boost the growth of the artificial intelligence pathology market during the forecast period. Additionally, high demand for e-diagnosis services in healthcare due to increasing government healthcare expenditure is fueling the market growth. In addition, the growing need to reduce diagnostic costs, improve patient care and reduce machine downtime is one of the factors accelerating the use of artificial intelligence in pathology and diagnostics.

The COVID-19 pandemic has highlighted the shortcomings of the current healthcare system and accelerated the adoption of digital technologies such as artificial intelligence to accurately analyze complex data sets, thereby reducing the administrative and operational burden on doctors. The growth of the market has been accelerated by the birth of start-up companies and the growing recognition of financing and investments. Healthcare startups have rapidly adopted AI-based systems and are gaining recognition in the form of favorable government support and funding from private investors and venture capitalists.

Delvens Industry Expert's Standpoint

The AI Pathology Market is anticipated to grow as AI technologies continue to evolve, becoming more capable of analyzing and interpreting complex pathological data. The integration of AI into pathology workflows has the potential to revolutionize diagnostic practices, reduce errors, enhance patient outcomes, and pave the way for personalized medicine. It represents a dynamic intersection of cutting-edge technology and the field of medicine, poised to revolutionize the way diseases are diagnosed, characterized, and treated. It has witnessed significant growth in recent years, driven by advancements in artificial intelligence technology, increasing adoption of digital pathology infrastructure, and a growing need for accurate and efficient diagnostic solutions.

Key Findings

The component segment is further fragmented into Managed Software and Services. The software segment is expected to account for a larger market size during the forecast period. This significant share is due to the widespread acceptance and use of Al-based software by pathologists. The software segment offers several advantages such as high adaptability, interoperability and automation of various pathological tasks such as image analysis, data extraction and report generation. These factors drive the adoption and further development of Al software in pathology, which offers significant potential for disease detection, diagnosis and treatment planning.

The Neural network segment is further bifurcated into generative adversarial network (GAN), convolutional neural network (CNN), recurrent neural network (RNN). The convolutional neural network (CNN) is the largest market during the forecast period. The significant growth rate of this segment is due to its exceptional ability to analyze complex visual data such as pathological images, extract relevant features and provide accurate diagnoses. In addition, CNN facilitates the localization and segmentation of regions of interest in images, allowing it to continuously learn and improve its performance over time using new data and feedback from pathologists.

The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period owing to the growing investments and reforms to modernize the pathology infrastructure in the region and the increasing adoption of digital pathology solutions.

Make an Inquiry Before Buying: https://www.delvens.com/Inquire-before-buying/pathology-ai-market-trends-forecast-till-2030

Regional Analysis

North America to Dominate the Market

North America is estimated to account for the largest market share during the forecast period. In North America, there is growing investments and reforms to modernize the pathology infrastructure in the region and the increasing adoption of digital pathology solutions.  

Moreover, the expansion of healthcare infrastructure and growing market availability of advanced AI technologies.

 Competitive Landscape

General Electric Co. (GE Healthcare)

Koninklijke Philips N.V

F. Hoffmann-La Roche Ltd

Hologic, Inc

Akoya Biosciences, Inc

Aiforia

Indica Labs Inc

OptraScan

Ibex Medical Analytics Ltd.

Mindpeak GmbH

Tribun Health

Siemens Healthineers

Zebra Medical Vision, Inc.

Riverain Technologies

IDx Technologies Inc.

NovaSignal Corporation

Vuno, Inc.

Aidoc

Neural Analytics

Imagen Technologies

Digital Diagnostics, Inc.

GE Healthcare

AliveCor Inc.

Proscia Inc

PathAl, Inc.

Tempus Labs, Inc.

Purchase the Research Report at: https://www.delvens.com/checkout/pathology-ai-market-trends-forecast-till-2030

Recent Developments

In April 2023, Indica Labs Inc. signed an agreement with Lunit Inc. The agreement helped to provide a fully interoperable solution between Indica Labs’ HALO AP image management software platform and Lunit’s suite of AI pathology products.  

In March 2022, Ibex Medical Analytics Ltd. Had partnered with Dedalus Group. Through this partnership, the company aimed to bring the power of artificial intelligence to digital pathology.

Reasons to Acquire

Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.  

Gain authentic and granular data access for the Pathology AI (Artificial Intelligence) Market to understand the trends and the factors involved in changing market situations.  

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.  

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope

The Pathology AI (Artificial Intelligence) Market is segmented into various segments such as component, neural network, application, end user and region:

Based on component

Software

Scanners

Based on the Neural network

CNN

GAN

RNN

Based on the Application

Drug Discovery

Diagnosis

Prognosis

Workflow

Education

Based on End User

Pharma

Biotech

Hospital Labs

Research

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

SALES@DELVENS.COM

[nandinipatil]

Digital Pathology Market Size, Share

Global Digital Pathology Market value

Scope of Global Digital Pathology Market:

The latest business intelligence report on the Digital Pathology Market offers a comprehensive overview of the pivotal aspects pertaining to this industry vertical. It incorporates an accurate assessment of historical records, projections, growth drivers, opportunities, challenges, and restraints, among others.

This research literature fragments the industry in terms of (segments). It individually assesses each segment based on its scope and provides valuable insights on its top revenue prospects. By using proven research methodologies, this document further includes granular insights into the geographical landscape while providing a 360-degree outlook of the growth trajectory of the highlighted regions.

The study on Digital Pathology Market further characterizes the competitive terrain by incorporating crucial data about the top industry players. It comprises of the detailed portfolio of each of the mentioned companies while deeply scrutinizing the major strategies adopted by them to enhance their global footprint. The crucial components such as product pricing, partnerships, mergers & acquisitions, collaborations, and major developments associated with each player are also unveiled in this report.

This report is specially curated to empower the existing players, stakeholders, and new entrants about the ongoing trends of this market which will allow them to make informed business-centric decisions.

Browse In-depth Market Research Report (300 Pages) on Digital Pathology Market:

Digital Pathology Market Companies:

F. Hoffmann-La Roche Ltd 

Ventana Medical Systems

Hamamatsu Photonics

3DHISTECH

Koninklijke Philips

Huron Digital Pathology

Visiopharm

Corista

Indica Labs

XIFIN & Leica Biosystem

Others

Regional Insights:

The regions covered in this Global Digital Pathology Market report are North America, Europe, Asia-Pacific, and Rest of the World. Based on country level, the market of Managed security service is subdivided into the U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, Southeast Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.

Global Digital Pathology Market Segmentation:

By Product:

Scanners

Software

Communication System

Storage System

By Type:

Human Pathology

Veterinary Pathology

By Application:

Teleconsultations

Disease Diagnosis

Drug Discovery

Training and Education

By End User:

Pharmaceutical & Biotechnology Companies

Hospitals and Reference Laboratories

Academic & Research Institutes

Healthcare Consulting Services Market is valued at USD 19.99 billion in 2022 and is expected to reach USD 35.85 billion in 2029, growing at a CAGR of 8.7% from 2022 to 2029.

[meditech-insights]

Drug Discovery Software Market was estimated at $2 billion in 2020 and is projected to grow at a CAGR of ~14% to cross $3.5 billion by 2025

The market for drug discovery software (such as ligand-based design, structure-based design, LIMS, ELN) is driven by rising R&D spend and pipeline, expanding scope and scale, increasing stringency of testing and regulations, growing number and size of biotechs, need for increasing cost efficiencies and reducing time to market, and the shift to web/cloud-based software.

The global Drug Discovery Software market is valued at ~$2 billion in 2020 and is expected to grow at a CAGR of ~14% to cross $3.5 billion by 2025. This growth is being fueled by rising R&D spending across the globe, need for cost-efficiency & faster time-to-market, stringent regulatory compliance/reporting, growing use of AI & ML in drug discovery, and rising demand for novel software solutions specifically made for biologics/cell & gene therapy.

Drug Discovery Software Market – Niche but Fast-Growing Market

The drug discovery software market is niche and expanding quickly, driven by the growing pressure on the pharma and biotech companies to cut costs in the research and preclinical stage of drug development, decrease timelines and improve transparency through deep learning software tools.

“Large players present in this segment are trying to consolidate the market by becoming a one stop shop. Moreover, companies are also considering to combine their solutions with bioinformatics and LIMS tools to have a competitive edge.” - Executive, Leading Drug Discovery Software Provider, US

Growing Focus on Developing AI/ML platforms for Drug Discovery

The advantages of using big data and AI/ML for drug discovery are being recognized by the life sciences industry more and more. Several AI/ML developments could be seen recently that are anticipated to disrupt the current drug discovery landscape.

For instance,

In Mar 2021, insitro, a ML-driven drug discovery and development company raised $400 million. In 2020, Optibrium launched Cerella, an AI software platform for drug discovery.

Explore Premium Report on Drug Discovery Software Market @ https://meditechinsights.com/drug-discovery-software-market/

Rising Demand for Software Solutions Specifically Designed for Biologics

Biologics are anticipated to expand rapidly during the drug discovery process. 50% of drugs currently in the preclinical phase are biologics. To leverage growth opportunities, companies are entering/expanding into biologics software space.

Transition to Web/Cloud-based Software

The drug discovery software industry is gradually shifting to cloud-based solutions as it can address most of the issues with on-premise installations and offer quick deployment, minimum upfront costs, high flexibility and scalability making it affordable for even small and medium size pharma/biotechs, academic research/universities and CROs.

Competitive Landscape Analysis of Drug Discovery Software Market

The global drug discovery software market is highly competitive and fragmented. Some of the key players include Dassault Systèmes, LabVantage, PerkinElmer, Schrodinger, Abbott, Healx, Optibrium, Instem, Chemical Computing Group, dotmatics, idbs, Titian, Biovia, Celsius, Genome Biologics, Atomwise, Standigm, insitro, and CytoReason.

For More Detailed Insights, Contact Us @ https://meditechinsights.com/contact-us/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com

[desaletushki]

Biopharmaceutical CMO & CRO Market Size, Trends, Forecast 2030

The global biopharmaceutical CMO and CRO market size is expected to reach USD 54.1 billion by 2030, registering a CAGR of 6.6% over the forecast period, according to a new report by Grand View Research, Inc. Post-pandemic the market is being driven by the growing interest of conventional drug developers in the biological therapeutics. At present, outsourcing has become a cost-saving strategy for small- to medium-sized biomanufacturers, as it helps in eliminating the need for establishing costly specialized facilities or hiring and training personnel. The post-pandemic recovery has started owing to positive pipeline developments across modalities.

For instance, Lonza and Moderna announced a ten-year collaboration for the commercial manufacturing of the COVID-19 vaccine. Such developments compensated for minor delays in clinical trials that occurred during the first half of 2020. The contract manufacturing organization segment is projected to unlock lucrative growth opportunities over the foreseeable future. The decline in R&D productivity and increased development costs have resulted in high pressure on biopharmaceutical manufacturers pertaining to short-term earnings and profit margins. This, in turn, has created lucrative opportunities for the CMOs & CROs to accelerate their business operations.

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-cmo-cro-market

The robustness of venture capital investments is one of the important supportive factors that has created opportunities for the growth of CMOs. Venture capital funds are considered more reliable than public equity. An increase in the availability of venture funds for life sciences is expected to bolster the growth of CMOs. However, these CMOs & CROs are expected to face competition from in-house departments of pharmaceutical & biotechnology companies. Several big pharma companies like Novartis announced to maintain and expand their biomanufacturing processes in-house over the coming years.

Biopharmaceutical CMO & CRO Market Report Highlights

Non-mammalian cell line-based bioproduction system is expected to be the fastest-growing segment over the forecast period

Innovative strategies are being implemented to identify and explore the potential of various microbes

This can be attributed to increasing investments in research programs for the development of novel therapeutics

The market in North America is recognized as a leader in biopharmaceutical innovations, thereby resulting in a large share of 33.97%

Moreover, the presence of several service providers and a higher concentration & number of biopharmaceutical firms in the region supports the market growth

The key players are involved in establishing mutually beneficial alliances with other emerging CMOs to scale up their production capabilities

Key Companies & Market Share Insights

The market is fragmented in nature due to the presence of a substantial number of developed as well as medium- to small-sized CMOs and CROs. Several market participants are privately held or are a part of private equity firms’ portfolios.The CMOs are integrating automation and innovative technologies at their plants to improve their capabilities in terms of project throughput and product quality. This has driven the interest of large molecule manufacturers in the CMOs to meet the growing demand for biologics.

Charles River Laboratories International, Inc.; PRA Health Sciences; ICON plc.; Pharmaceutical Product Development, LLC; LabCorp; and Parexel International Corporation are engaged in offering contract research services for large molecule production. Market players focus on various business strategies including mergers, acquisitions, product launches, etc. For instance, in December 2021, Discovery Life Sciences completed and announced the acquisition of In Vitro ADMET Laboratories (IVAL). With this move, the company aims to expand its skilled workforce allowing them to competently cater to the rising outsourcing of research activities.

Request Free Sample Report: https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-cmo-cro-market

[medi-techinsights]

Global Drug Discovery Software Market is projected to grow at a healthy CAGR of 14% to cross $3.5 billion by 2025

The global drug discovery software market (such as ligand-based design, structure-based design, LIMS, ELN) is driven by the increasing R&D spend and pipeline, expanding scope and scale, increasing stringency of testing and regulations, growing number and size of biotechs, need for increasing cost efficiencies and reducing time to market, and move towards web/cloud-based software.

Drug Discovery Software Market – Niche but Fast-Growing Market

The drug discovery software market is niche and growing rapidly, driven by the rising pressure on the pharma and biotech companies to cut costs in the research and preclinical stage of drug development, reduce timelines and improve transparency through deep learning software tools.

“Large players present in this segment are trying to consolidate the market by becoming a one stop shop. Moreover, companies are also considering to combine their solutions with bioinformatics and LIMS tools to have a competitive edge.” - Executive, Leading Drug Discovery Software Provider, United States

Increasing Focus on Developing AI/ML platforms

The life sciences industry is increasingly recognizing the benefits offered by big data and AI/ML in drug discovery. Several AI/ML developments could be seen recently that are expected to disrupt the current drug discovery landscape. For instance, in Mar 2021, insitro, a ML-driven drug discovery and development company raised $400 million. In 2020, Optibrium launched Cerella, an AI software platform for drug discovery.

Growing Demand for Efficient Software Solutions

Biologics are expected to experience strong growth in the drug discovery phase. 50% of drugs currently in the preclinical phase are biologics. To leverage growth opportunities, companies are entering/expanding into biologics software space.

Transition to Web/Cloud-based Software

The drug discovery software market is slowly moving towards cloud-based solutions as it can address most of the issues with on-premise installations and provide quick deployment, minimum upfront costs, high flexibility and scalability making it affordable for even small and medium size pharma/biotechs, academic research/universities and CROs.

Competitive Landscape Analysis: Drug Discovery Software Market

The global drug discovery software market is highly competitive and fragmented. The top market players are Dassault Systèmes, LabVantage, PerkinElmer, Schrodinger, Abbott, Healx, Optibrium, Instem, Chemical Computing Group, dotmatics, idbs, Titian, Biovia, Celsius, Genome Biologics, Atomwise, Standigm, insitro, and CytoReason.

Get Customized Report on Drug Discovery Software Market @ https://meditechinsights.com/drug-discovery-software-market/

[colinwilson11]

[mrfrblogresearch02]

Digital Pathology Market share, Development Data, Growth Analysis & Forecast 2027

Market Overview

The growing number of innovations in the areas of pathology would further increase the size of the market to a great deal, in the next six years. According to Market Research Future (MRFR), the global digital pathology market Size is estimated for valuation of over USD 8,305.6 MN. In its recently published analysis, MRFR also asserts that the market would register a double-digit CAGR over 13.04% throughout the forecast period.

Advantages like speedy diagnosis processes are facilitating treatments, which drive the market ahead. Additionally, the advanced medical services and the burgeoning healthcare sector worldwide are fostering the growth of the digital pathology market. The demand for fast proceedings of treatments, with an accurate diagnosis, is rising, which results in the growth of the digital pathology market.

The transition to cloud pathology is a prominent trend, observed during the analysis, which is expected to push up the growth in the market. This is due to the cloud-based delivery of solutions, which is cost-effective, take minimal installation time without needing a sophisticated IT infrastructure.

Integration of Artificial Intelligence (AI) technologies into digital pathology is another such trend noticed during MRFR analysis. Investors are ready to invest hugely in start-ups attempting to apply artificial intelligence. Many entrants are getting benefitted with substantial grants. Technology experts think that machine learning and other sophisticated technologies could assist pathologists, making them more precise in their analysis.

AI has the capacity of turning pathology equipment into a digital zone. However, AI experts need to ensure that AI technology can reliably process reams of data, and the software is seamlessly integrated into the workflow of pathologists. Advances in the automation enable pathologists to spend more time on tougher cases, providing them with insights about the issues that human eyes can’t detect.

Global Digital Pathology Market – Segments

By Type: Human Pathology and Animal Pathology.

By Application: mHealth, Telemedicine, Disease Diagnosis, and Drug Discovery, among others.

By End Users: Hospital/Clinics, Pharmaceutical Companies, Reference Laboratories, and Research Institutes, among others.      

By-Products: Storage Server Systems, Scanners, and Software, among others.      

By Regions: Asia Pacific, Europe, North America, and Rest-of-the-World.

Global Digital Pathology Market – Regional Analysis

North America market leads the global digital pathology market with a significant share. The well-developed healthcare sector in the US & Canada, together with high per capita healthcare expenditures of these economies drive the regional market growth. Moreover, the presence of some of the matured market players fuels growth in the regional market. The market is further expected to create a substantial revenue pocket throughout the forecast period (2017-2023).

The digital pathology market in the European region takes the second lead. The market is predominantly driven by the availability of funds for research, well-developed healthcare infrastructure, huge patient population, and government support for R&D. The UK and Germany, backed by high healthcare expenditures majorly propel the growth of the Europe market.

The Asia Pacific digital pathology is emerging as a promising market globally. Expected to become the fastest-growing market for digital pathology, The APAC region is estimated to grow rapidly over the projected period. Moreover, factors such as the increasing healthcare expenditures along with favorable government policies of developing economies like India and China foster the regional market growth.

Digital Pathology Market   - Competitive Analysis

Highly competitive, the digital pathology market appears to be fragmented with the presence of several large and small players. Many well-established players, along with the new entrants, form a competitive landscape. Through strategic initiatives, such as acquisition, expansion, collaboration, and product/technology launch, these players try to gain a competitive advantage in this market. Substantial investments are transpired in R&D to develop a completely different technology compared to their competition.

Major Players:

Players leading the digital pathology market include Danaher Corporation (US), Olympus Corporation (Japan), Inspirata (US), Huron Digital Pathology Inc. (Canada), 3DHISTECH Ltd. (Hungary), Koninklijke Philips N.V. (the Netherlands), Microdimensions GmbH (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Mikroscan Technologies, Inc. (US), and Definiens (Germany), among others.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

[industryinsights]

Biochips Market Size, Share Analysis, Key Companies, and Forecast To 2027

The biochips market has been growing significantly over the past few years. Biochips market size is expected to grow significantly over the forecast period. The market held a market value of USD 7,300 million in 2017 and is projected to grow at a CAGR of 16.6% over the forecast period.

Increasing technological advancements in biochips is a key driving force behind the growth of the market. Moreover, increasing the adoption of personalized medicine in cancer genomics applications are fostering the growth of the market. Furthermore, growing applications of biochips would help in boosting the growth in the market during the review period.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/7063

Moreover, increasing mergers and acquisition, growing collaborations and partnerships, and product launches are some of the latest trends in the global biochips market. Furthermore, factors such as the increasing clinical trials and drug discovery activities, advancements such as lab-on-chip and splice variants, the wider application area of microarray, and government initiatives & support are expected to develop new market opportunities.

On the flip side, substantially high cost of the instruments and stringent regulatory guidelines are some of the significant factors inhibiting the growth of the global biochips market. Also, the lack of standardization in microarray data, and skilled professionals may restrain the growth of the market. Nevertheless, factors such as the need for early cancer detection, diagnosis, and large-scale DNA/gene chip initiatives are some of the predominant factors expected to support market growth over the assessment period.

Global Biochips Market - Segments

The report is segmented into four key market dynamics to widen the scope of understanding,

By Type : DNA Chips, Lab-on-a-Chip, Cell Arrays, Tissue Arrays, and Protein Chips, among others.

By Technology: Microarrays and Microfluidics.

By End-user: Biotechnology & Pharmaceutical Companies, Hospitals, and Diagnostics Centers, among others.

By Regions: Asia Pacific, North America, Europe, and the Rest-of-the-World.

Global Biochips Market - Regional Analysis

North America dominates the global biochips market followed by Europe. High per-capita healthcare expenses and the presence of major market players and well-established healthcare sector are the major factors driving the biochips market in North America. Furthermore, increasing technological advancement, growing research & development activities, increasing cancer incidences, and increasing government support are fostering the regional market growth.

The biochips market in the European region holds hold the second-largest share in the global market. The presence of strong academic & research base and availability of funding for research in the European countries drives the regional market growth. Moreover, factors such as improving healthcare infrastructure, growing prevalence of chronic diseases, increasing government expenditure, growing drug discovery, and development activities are acting as a significant tailwind to the biochips market in Europe.

The Asia pacific biochips market is an emerging market, globally. Increasing government focus on biomedical and biotechnology sector and the growing number of target population in the region foster the regional market growth. The biochips market in the rapidly developing economies, China and India are emerging due to an improved lifestyle, growing awareness about biochips & their benefits, and increasing government support.

In India, top pharma companies are now partly foreign-owned and are already generating more than half of their sales outside the country. Besides, economic growth has increased healthcare expenses in India.

Global Biochips Market - Competitive Analysis

Characterized by the presence of many large and small players, the global biochips market appears to be highly competitive as well as fragmented. These well-established players incorporate strategic initiatives such as acquisition, collaboration, expansion, and product launch to gain a competitive advantage in this market. Players operating in the biochips market compete based on pricing, availability, brand, and variety.

Major Players:

Players leading the global biochips market include Fluidigm Corporation, Perkinelmer, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, Cepheid Inc., GE Healthcare, Illumina, Inc., Thermo Fisher Scientific, Inc, and Roche Diagnostics among others.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/biochips-market-7063

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Have a Look at Related Reports:

Pharmaceutical Analytical Testing Outsourcing Market - https://www.medgadget.com/2019/11/pharmaceutical-analytical-testing-outsourcing-market-driven-by-increasing-drug-development-activity-in-north-america-europe-mrfr-published-global-analysis-by-2023.html

Radiopharmaceutical Market - https://www.medgadget.com/2019/11/radiopharmaceutical-market-overview-and-manufacturing-cost-structure-global-size-share-business-strategy-investments-by-major-players-and-forecast-to-2023.html

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

[sampada92]

Global Mass Spectrometry Market Status by Manufacturers, Type and Application Forecast 2025

Mass Spectrometry is an analytical method to separate and sort the chemical substances based on their mass. The technique aids to analyse various substances present in a given sample. In this method, the sample is converted into gaseous ions and these ions are analysed using their mass to charge ratios and the relative abundance of each ion is recorded. The instrumentation of a typical mass spectrometer includes ion source, analyser and a detector system.  

In the recent years there has been an increase in application areas of mass spectrometry technique in life sciences industry including pharmaceutical, biotechnology, and other manufacturing areas. This increasing application area is expected to drive the market growth in the years to come. In addition, growing demand for new & advanced instruments across the globe; rise in investments in R&D by major market players to develop advanced products; and growth in the number of contract research organizations (CROs) can be the other factors attributing to the growth of mass spectrometry market.

Browse Complete Report @ https://globalmarketforecasts.com/selectedReport/20/Global-Mass-Spectrometry-Market-Analysis-and-Forecast-to-2025

Mass spectrometry has emerged as a dominant analytical tool applied to the pharmaceutical and health life sciences sector. Advance technologies such as ion mobility spectrometry and capillary electrophoresis is being used for the separation of complex biological mixtures such as derived peptide products. Mass spectrometry provides increased sensitivity over other analytical systems, owing to reduced background intrusion and superior specificity from characteristic fragmentation patterns to detect unknown compounds. In addition, it can also identify existence of suspected compound and data regarding molecular weight of the compound in the mixture, and provides data about isotopic abundance of elements and chemical data determined for a short term.  

Segmentation:                    

Based on instrument, the market can be segmented into ion source, mass analysers, and detector systems.

The mass analysers segment based on the technology is further sub segmented into magnetic mass analysers, quadrupole mass analysers, time of flight (ToF) analysers, and others. Based on technology, the global mass spectrometry market can be segmented into liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS), inductively coupled plasma mass spectrometry (ICP-MS), quadrupole-time of flight liquid chromatography-mass spectrometry, ionization time of flight spectrometry, and others.

Based on application, the mass spectrometry market can be segmented into drug discovery & testing, clinical research, proteomics, forensic toxicology, and others.

Based on end user, the market can be segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), and others.  

Get Sample Report @ https://globalmarketforecasts.com/request-for-sample/20

Global Mass Spectrometry Market Players List:

Thermo Fisher Scientific

Danaher Corporation

Bio-Rad Laboratories, Inc.

Agilent Technologies

Waters Corporation

PerkinElmer

Analytik Jena

Rigaku Corporation

Bruker Corporatio

bioMerieux SA  

Regional Overview:

The mass spectrometry market based on the region is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North American market is further segmented into US and Canada. The Europe market is categorized into UK, Germany, and France. The market for mass spectrometry in Asia Pacific is segmented into Japan, China, and India. The Latin American market is categorized as Mexico and Brazil. The Middle East & Africa region is classified as South Africa, Saudi Arabia, and UAE. The mass spectrometry market report includes market size and analysis for all the above-mentioned regions and countries for instruments, technology, application, and end user.  

Table of Contents:                                                                                                    

Chapter 1: Introduction

Chapter 2: Executive Summary

Chapter 3: Global Mass Spectrometry Market – Market Dynamics

Drivers

Restraints

Opportunities

Chapter 4: Global Mass Spectrometry Market – By Instrument

Ion Source

Mass Analyzers

Detector Systems

Quadrupole Mass Analyzers

Magnetic Mass Analyzers

Time of Flight (TOF) Analyzers

Others

 TOC Continued       

About Us:

Global Market Forecasts is a global business intelligence and consulting firm aimed at assisting our clients to make critical business decisions and achieve exponential growth in their business. We focus on emerging markets and technologies, and insights on niche markets. Our reports include information on recent trends and innovations. Our pool of more than 300 off-shelf reports in each industry and customized reports based on the client’s requirement aids our client in making faster business decisions.

Contact Us:

Kumar Primus,

Hadapsar Industrial Estate,

Hadapsar, Pune, Maharashtra 411013                                            

Phone: +1-201-564-4683

Email: sales@globalmarketforecasts.com

[techscimarketresearch]

Genetic Engineering Tool Market to Grow with Advancing Biotech Sector During the Forecast Period | TechSci Research

Expanding genetic research is driving the growth in Global Genetic Engineering Tool Market in the forecast period, 2022-2026.

According to TechSci Research report, “Genetic Engineering Tool Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2016-2026”, the global genetic engineering tool market has a potential to project an impressive CAGR toward future growth in the period, 2022-2026, on the account of increasing demand for genetically modified organisms. GMOs have extended applications in the agriculture sector too and increasing instances of modified plants to enhance their growth, their resistance from infectious diseases, etc. is further driving the growth of the global genetic engineering tool market in the upcoming five years.

Also, surging demand for the advanced medication, genomic medicine, precision drugs, etc. along with the expanding pharmaceutical industry is supporting the growth of the global genetic engineering tool market in the next five years. Increasing demand for the gene therapy for the treatment of diseases like cancer, etc. is also substantiating the growth of the global genetic engineering tools market in the future five years.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Genetic Engineering Tool Market"

https://www.techsciresearch.com/report/genetic-engineering-tool-market/8085.html

The global genetic engineering tool market is segmented on the basis of type, therapeutic area, end user, competitional landscape, and regional distribution. Based on type, the market is further fragmented into genome scale editing tools, and genome scale engineering tools. The market further segments genome scale editing tools into CRISPR, MAGE, CRMAGE, CREATE, and others.

Clustered regularly interspaced short palindromic repeats (CRISPR) is a gene editing tool and it is anticipated to hold the largest revenue shares of the market and dominate the market segment in the upcoming five years due to its increasing popularity and increased applications in various sectors. Multiplex Automated Genomic Engineering (MAGE) is gaining recent popularity due to its efficiency over other methods.

Developed by Wyss Institute at Harvard Medical School, the procedure is much faster, cheaper, and easier for genetic researchers to create organisms with novel functions that they can use for a variety of purposes, such as making chemicals and medicine, developing biofuels, or further studying and understanding the genes that can cause harmful mutations in humans. Genome scale engineering sub-segment includes promoter engineering, ribosomal binding site (RBS) engineering, synthetic small regulatory RNA, and others.

Some of the market players, dominating the global market are:

Thermo Fisher Scientific Inc

CRISPR Therapeutics AG

Editas Medicine, Inc.

Intellia Therapeutics, Inc

Merck KGaA

Horizon Discovery Ltd

GeneCopoeia Inc

Takara Bio Inc

Sangamo Therapeutics, Inc.

Genscript Biotech Corporation

These market players along with new market entrants, are focused on extensive research and bringing innovative and advanced products. Technologically advanced manufacturing of the pharmaceutical products and therapeutic processes would aid in decreasing the cost of the production and aid the players in managing their investments. Moreover, initiatives from the government and private fundings would support the global genetic engineering tool market growth indirectly.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=8085

Customers can also request for 10% free customization on this report.

“North America region is anticipated to dominate the global market analysis on the grounds of most of the researches based on cancer and other chronic disease treatment being conducted in the larger economies like the United States, and Canada. Also, the rapidly increasing market players in the region are supporting the growth of the global genetic engineering tool market in the upcoming five years. Additionally, increasing research and development of pharmaceutical products are further supporting the growth of the global genetic engineering tool market in the next five years.

Moreover, private & governmental investments in the genetic engineering are further substantiating the growth of the global genetic engineering tool market in the future five years. Asia Pacific region is also anticipated to register significant growth in the consecutive five years in future on the account of sudden increase in the population accounting for higher demands for high yielding food crops. Technological advancement along with development of innovative methods of genetic engineering support global genetic engineering tool market in the future five years. New market players are advised to conduct extended research and formulate better methods and experiment kits for their brand establishments,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Genetic engineering tool Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2016-2026 Segmented By Type (Genome Scale Editing Tools {CRISPR, MAGE, CRMAGE, CREATE, Others} v/s Genome Scale Engineering Tools {Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others}), By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer’s Disease, Obesity, Others), By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others), By Region”, has evaluated the future growth potential of global genetic engineering tool and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global genetic engineering tool market.

Browse Related Reports:

Precision Dosing Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, Segmented By Patient Type (Pediatrics, Geriatrics, Patients on Polypharmacy, Patients with End Organ Dysfunction, Others), By Tools (Physiologically-Based Pharmacokinetic (PBPK) Modeling v/s Non-Linear Mixed Effects (NLME) Modeling), By Software (Web-Based v/s Desktop-Based), By Drug Class (Antibiotics, Antimycotics, Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Others), By Region 2016-2026

https://www.techsciresearch.com/report/precision-dosing-market/8000.html

Organ on Chip Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2016-2026 Segmented By Type (Liver, Heart, Lung, Kidney, Others), By Offering (Products v/s Services), By Material Type (Polymer, PDMS, Glass, Silicon, Others), By Application (Physiological Model Development, Drug Discovery, Toxicological Research, Molecular Biology, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Cosmetic Industry, Others), By Region 2016-2026

https://www.techsciresearch.com/report/organ-on-chip-market/7763.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York ��� 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/